Danaher Corporation vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Danaher Corporation trades at $200.72 (market cap $140.88B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $29.84. The key difference: Danaher Corporation pays a 0.8% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and MicroSectors FANG and Innovation 3X Leveraged ETN is trading nearer its 52-week high, Danaher Corporation nearer its low. Which is the better fit depends on your goals.
| DHR | FNGU | |
|---|---|---|
Market Cap | $140.88B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $36.15 |
52-Week Low | $161.91 | $13.73 |
Enterprise Value | $153.66B | — |
Dividend Yield | 0.8% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $200.16, up 0.56% today, with a bullish technical signal from moving averages and strong analyst support. The company reported Q1 2026 EPS of $2.06, beating estimates of $1.94, marking the third consecutive quarterly beat. Revenue for 2025 was $24.57 billion with a net income margin of 14.89%, though margins have compressed from prior years. Recent news includes the acquisition of Masimo and a $172.5 million legal settlement finalized in April 2026.
The outlook remains positive with a consensus price target of $211.33, implying ~5.6% upside, supported by 69% buy ratings. Key risks include margin pressure, integration challenges from acquisitions, and macroeconomic sensitivity. The stock offers a dividend yield from its $0.40 quarterly payout, with solid cash flow generation offsetting debt levels.
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $27.9, down 2.58% on the day. Technical indicators show a bullish moving average signal but caution from oscillators, with the 12-day RSI at 70.17 indicating potential overbought conditions. Recent news highlights extreme volatility, with a 16% single-session loss reported on June 5, 2026, underscoring the inherent risks of leveraged products.
The outlook for FNGU is highly speculative, driven by daily rebalancing and leverage amplifying both gains and losses. Investment opportunity exists for aggressive traders betting on short-term tech sector strength, but risks include rapid capital erosion during market downturns and structural costs from the 0.95% fee and leverage decay, as noted in recent financial media.
Trailing returns across standard periods
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →